

**Table S1** Characteristics of the 76 CABG patients and preoperative medications

Characteristics	Number of patients (% of the total patients)
Sex	
Male	64 (84.21%)
Female	12 (15.79%)
Age (year)	
≤65	45 (59.21%)
>65	31 (40.79%)
BMI	
<18.5	1 (1.32%)
>18.5<24	21 (27.63%)
≥24	54 (71.05%)
Hypertension	52 (68.42%)
Stage I	2 (2.63%)
Stage II	17 (22.37%)
Stage III	33 (43.42%)
Dyslipidemia (TC ≥6.2 mmol/L or LDL ≥4.1 mmol/L or TG ≥2.3 mmol/L)	25 (32.89%)
Current smoker	27 (35.53%)
Anti-hypertensive drugs <sup>#</sup>	73 (96.05%)
Statins <sup>##</sup>	69 (90.79%)
Coronary dilating drugs	68 (89.47%)
Anti-thrombotic drugs	76 (100%)

<sup>#</sup>Non-hypertensive patients who received beta-blockers at least 24 hours before CABG to reduce the incidence or complications of postoperative atrial fibrillation were also counted. <sup>##</sup>Patients without dyslipidemia who received statins at least 24 hours before CABG to reduce risks of postoperative major adverse cardiovascular and cerebral events were also counted. CABG, coronary artery bypass surgery; BMI, body mass index; TC, total cholesterol; TG, triglyceride; LDL, low-density lipoprotein cholesterol.